23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We conducted a single-institution phase II clinical trial evaluating the safety and efficacy of combination chemoimmunotherapy followed by radioimmunotherapy consolidation and rituximab maintenance as front-line treatment in indolent lymphomas.

          Related collections

          Author and article information

          Journal
          Clin Lymphoma Myeloma Leuk
          Clinical lymphoma, myeloma & leukemia
          Elsevier BV
          2152-2669
          2152-2669
          Dec 2011
          : 11
          : 6
          Affiliations
          [1 ] Rush University Medical Center, Chicago, IL 60612, USA. reem_karmali@rush.edu
          Article
          S2152-2650(11)00069-3
          10.1016/j.clml.2011.04.009
          21700527
          7c93c419-c39f-4973-aba5-84014093ca38
          History

          Comments

          Comment on this article